Risk Prediction Models and Novel Prognostic Factors for Heart Failure with Preserved Ejection Fraction: A Systematic and Comprehensive Review

Overview

Journal Curr Pharm Des

Publisher Bentham Science Publishers

Date 2023 Aug 30

PMID 37644795

Authors

Shanshan Lin

Zhihua Yang

Yangxi Liu

Yingfei Bi

Yu Liu

Zeyu Zhang

Xuan Zhang

Zhuangzhuang Jia

Xianliang Wang

Jingyuan Mao

Affiliations

Soon will be listed here.

Abstract

Background: Patients with heart failure with preserved ejection fraction (HFpEF) have large individual differences, unclear risk stratification, and imperfect treatment plans. Risk prediction models are helpful for the dynamic assessment of patients' prognostic risk and early intensive therapy of high-risk patients. The purpose of this study is to systematically summarize the existing risk prediction models and novel prognostic factors for HFpEF, to provide a reference for the construction of convenient and efficient HFpEF risk prediction models.

Methods: Studies on risk prediction models and prognostic factors for HFpEF were systematically searched in relevant databases including PubMed and Embase. The retrieval time was from inception to February 1, 2023. The Quality in Prognosis Studies (QUIPS) tool was used to assess the risk of bias in included studies. The predictive value of risk prediction models for end outcomes was evaluated by sensitivity, specificity, the area under the curve, C-statistic, C-index, etc. In the literature screening process, potential novel prognostic factors with high value were explored.

Results: A total of 21 eligible HFpEF risk prediction models and 22 relevant studies were included. Except for 2 studies with a high risk of bias and 2 studies with a moderate risk of bias, other studies that proposed risk prediction models had a low risk of bias overall. Potential novel prognostic factors for HFpEF were classified and described in terms of demographic characteristics (age, sex, and race), lifestyle (physical activity, body mass index, weight change, and smoking history), laboratory tests (biomarkers), physical inspection (blood pressure, electrocardiogram, imaging examination), and comorbidities.

Conclusion: It is of great significance to explore the potential novel prognostic factors of HFpEF and build a more convenient and efficient risk prediction model for improving the overall prognosis of patients. This review can provide a substantial reference for further research.

References

Konishi M, Kagiyama N, Kamiya K, Saito H, Saito K, Ogasahara Y . Impact of sarcopenia on prognosis in patients with heart failure with reduced and preserved ejection fraction. Eur J Prev Cardiol. 2021; 28(9):1022-1029. DOI: 10.1093/eurjpc/zwaa117. View

Sawaki D, Czibik G, Pini M, Ternacle J, Suffee N, Mercedes R . Visceral Adipose Tissue Drives Cardiac Aging Through Modulation of Fibroblast Senescence by Osteopontin Production. Circulation. 2018; 138(8):809-822. DOI: 10.1161/CIRCULATIONAHA.117.031358. View

Tromp J, Khan M, Klip I, Meyer S, de Boer R, Jaarsma T . Biomarker Profiles in Heart Failure Patients With Preserved and Reduced Ejection Fraction. J Am Heart Assoc. 2017; 6(4). PMC: 5532986. DOI: 10.1161/JAHA.116.003989. View

Wu C, Tsai H, Su M, Wu Y, Hwang J, Lin J . Evolutional change in epicardial fat and its correlation with myocardial diffuse fibrosis in heart failure patients. J Clin Lipidol. 2017; 11(6):1421-1431. DOI: 10.1016/j.jacl.2017.08.018. View

Shang X, Lu R, Liu M, Xiao S, Dong N . Heart rate and outcomes in patients with heart failure with preserved ejection fraction: A dose-response meta-analysis. Medicine (Baltimore). 2017; 96(43):e8431. PMC: 5671878. DOI: 10.1097/MD.0000000000008431. View

Sun Y, Wang N, Li X, Zhang Y, Yang J, Tse G . Predictive value of H FPEF score in patients with heart failure with preserved ejection fraction. ESC Heart Fail. 2021; 8(2):1244-1252. PMC: 8006728. DOI: 10.1002/ehf2.13187. View

Luedike P, Alatzides G, Papathanasiou M, Heisler M, Pohl J, Lehmann N . Predictive potential of macrophage migration inhibitory factor (MIF) in patients with heart failure with preserved ejection fraction (HFpEF). Eur J Med Res. 2018; 23(1):22. PMC: 5935947. DOI: 10.1186/s40001-018-0321-1. View

Zhou Y, Fu L, Sun J, Zhu Z, Xing Z, Zhou S . Association Between Metabolic Syndrome and an Increased Risk of Hospitalization for Heart Failure in Population of HFpEF. Front Cardiovasc Med. 2021; 8:698117. PMC: 8476762. DOI: 10.3389/fcvm.2021.698117. View

Sato Y, Yoshihisa A, Oikawa M, Nagai T, Yoshikawa T, Saito Y . Hyponatremia at discharge is associated with adverse prognosis in acute heart failure syndromes with preserved ejection fraction: a report from the JASPER registry. Eur Heart J Acute Cardiovasc Care. 2019; 8(7):623-633. DOI: 10.1177/2048872618822459. View

10.

Bayes-Genis A, De Antonio M, Vila J, Penafiel J, Galan A, Barallat J . Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3. J Am Coll Cardiol. 2013; 63(2):158-66. DOI: 10.1016/j.jacc.2013.07.087. View

11.

Zhen Z, Liang W, Tan W, Dong B, Wu Y, Liu C . Prognostic significance of blood urea nitrogen/creatinine ratio in chronic HFpEF. Eur J Clin Invest. 2022; 52(7):e13761. DOI: 10.1111/eci.13761. View

12.

Matsui Y, Jia N, Okamoto H, Kon S, Onozuka H, Akino M . Role of osteopontin in cardiac fibrosis and remodeling in angiotensin II-induced cardiac hypertrophy. Hypertension. 2004; 43(6):1195-201. DOI: 10.1161/01.HYP.0000128621.68160.dd. View

13.

Thawabi M, Hawatmeh A, Studyvin S, Habib H, Shamoon F, Cohen M . Cardiac troponin and outcome in decompensated heart failure with preserved ejection fraction. Cardiovasc Diagn Ther. 2017; 7(4):359-366. PMC: 5582062. DOI: 10.21037/cdt.2017.03.17. View

14.

Harada T, Yamaguchi M, Omote K, Iwano H, Mizuguchi Y, Amanai S . Cardiac Power Output Is Independently and Incrementally Associated With Adverse Outcomes in Heart Failure With Preserved Ejection Fraction. Circ Cardiovasc Imaging. 2022; 15(2):e013495. DOI: 10.1161/CIRCIMAGING.121.013495. View

15.

Roy C, Lejeune S, Slimani A, de Meester C, Ahn As S, Rousseau M . Fibroblast growth factor 23: a biomarker of fibrosis and prognosis in heart failure with preserved ejection fraction. ESC Heart Fail. 2020; 7(5):2494-2507. PMC: 7524237. DOI: 10.1002/ehf2.12816. View

16.

Matsuo N, Miyoshi T, Takaishi A, Kishinoue T, Yasuhara K, Tanimoto M . High Plasma Docosahexaenoic Acid Associated to Better Prognoses of Patients with Acute Decompensated Heart Failure with Preserved Ejection Fraction. Nutrients. 2021; 13(2). PMC: 7911271. DOI: 10.3390/nu13020371. View

17.

Kanagala P, Arnold J, Khan J, Singh A, Gulsin G, Squire I . Plasma P-selectin is a predictor of mortality in heart failure with preserved ejection fraction. ESC Heart Fail. 2021; 8(3):2328-2333. PMC: 8120355. DOI: 10.1002/ehf2.13280. View

18.

Sueta D, Yamamoto E, Nishihara T, Tokitsu T, Fujisue K, Oike F . H2FPEF Score as a Prognostic Value in HFpEF Patients. Am J Hypertens. 2019; 32(11):1082-1090. DOI: 10.1093/ajh/hpz108. View

19.

Pocock S, Ariti C, McMurray J, Maggioni A, Kober L, Squire I . Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. Eur Heart J. 2012; 34(19):1404-13. DOI: 10.1093/eurheartj/ehs337. View

20.

Sakaguchi E, Yamada A, Naruse H, Hattori H, Nishimura H, Kawai H . Long-term prognostic value of changes in left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction. Heart Vessels. 2022; 38(5):645-652. DOI: 10.1007/s00380-022-02211-y. View